慢性乙型肝炎肝纤维化逆转评估方法的探讨

A discussion of the methods for the assessment of chronic hepatitis B-related liver fibrosis regression

抗病毒治疗可以逆转乙型肝炎肝纤维化和早期肝硬化，但对纤维化逆转的评估目前仍存在争议。肝穿刺活组织检查方面，作为“金标准”仍存在局限性。无创诊断方面，瞬时弹性成像干扰因素较多，血清学指标目前临床研究证据较少，因此，用于评估纤维化逆转仍需要更多临床研究证据支持。

l Antiviral therapy could reverse hepatitis B-related liver fibrosis and early-stage cirrhosis. However, the assessment of fibrosis regression remains controversial. As the gold standard for assessment, liver biopsy has its own limitations. In terms of non-invasive assessment, there are many interfering factors for transient elastography and less clinical evidence for the use of serum markers. Therefore, further evidence from clinical studies is still needed to determine the role of non-invasive methods in evaluating fibrosis regression.